113 related articles for article (PubMed ID: 24273885)
1. Vesicular phospholipid gels using low concentrations of phospholipids for the sustained release of thymopentin: pharmacokinetics and pharmacodynamics.
Zhong Y; Chen L; Zhang Y; Li W; Sun X; Gong T; Zhang Z
Pharmazie; 2013 Oct; 68(10):811-5. PubMed ID: 24273885
[TBL] [Abstract][Full Text] [Related]
2. Multivesicular liposomes for the sustained release of thymopentin: stability, pharmacokinetics and pharmacodynamics.
Zuo J; Gong T; Sun X; Huang Y; Peng Q; Zhang Z
Pharmazie; 2012 Jun; 67(6):507-12. PubMed ID: 22822538
[TBL] [Abstract][Full Text] [Related]
3. Thymopentin nanoparticles engineered with high loading efficiency, improved pharmacokinetic properties, and enhanced immunostimulating effect using soybean phospholipid and PHBHHx polymer.
Wu C; Zhang M; Zhang Z; Wan KW; Ahmed W; Phoenix DA; Elhissi AM; Sun X
Mol Pharm; 2014 Oct; 11(10):3371-7. PubMed ID: 24641274
[TBL] [Abstract][Full Text] [Related]
4. Box-Behnken optimization design and enhanced oral bioavailability of thymopentin-loaded poly (butyl cyanoacrylate) nanoparticles.
Jin X; Huang A; Ping Q; Cao F; Su Z
Pharmazie; 2011 May; 66(5):339-47. PubMed ID: 21699067
[TBL] [Abstract][Full Text] [Related]
5. Thymopentin-loaded phospholipid-based phase separation gel with long-lasting immunomodulatory effects: in vitro and in vivo studies.
Zhang T; Qin XY; Cao X; Li WH; Gong T; Zhang ZR
Acta Pharmacol Sin; 2019 Apr; 40(4):514-521. PubMed ID: 30002492
[TBL] [Abstract][Full Text] [Related]
6. Novel thymopentin release systems prepared from bioresorbable PLA-PEG-PLA hydrogels.
Zhang Y; Wu X; Han Y; Mo F; Duan Y; Li S
Int J Pharm; 2010 Feb; 386(1-2):15-22. PubMed ID: 19895878
[TBL] [Abstract][Full Text] [Related]
7. Vesicular phospholipid gel-based depot formulations for pharmaceutical proteins: development and in vitro evaluation.
Tian W; Schulze S; Brandl M; Winter G
J Control Release; 2010 Mar; 142(3):319-25. PubMed ID: 19925833
[TBL] [Abstract][Full Text] [Related]
8. Sustained delivery of cytarabine-loaded vesicular phospholipid gels for treatment of xenografted glioma.
Qi N; Cai C; Zhang W; Niu Y; Yang J; Wang L; Tian B; Liu X; Lin X; Zhang Y; Zhang Y; He H; Chen K; Tang X
Int J Pharm; 2014 Sep; 472(1-2):48-55. PubMed ID: 24914829
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
Zhang Y; Zhong Y; Hu M; Xiang N; Fu Y; Gong T; Zhang Z
Drug Dev Ind Pharm; 2016; 42(7):1042-9. PubMed ID: 26558908
[TBL] [Abstract][Full Text] [Related]
10. Vesicular phospholipid gels as drug delivery systems for small molecular weight drugs, peptides and proteins: State of the art review.
Breitsamer M; Winter G
Int J Pharm; 2019 Feb; 557():1-8. PubMed ID: 30572079
[TBL] [Abstract][Full Text] [Related]
11. Thymopentin-loaded pH-sensitive chitosan nanoparticles for oral administration: preparation, characterization, and pharmacodynamics.
Zheng AP; Wang JC; Lu WL; Zhang X; Zhang H; Wang XQ; Zhang Q
J Nanosci Nanotechnol; 2006; 6(9-10):2936-44. PubMed ID: 17048501
[TBL] [Abstract][Full Text] [Related]
12. Sterilization stability of vesicular phospholipid gels loaded with cytarabine for brain implant.
Qi N; Tang X; Lin X; Gu P; Cai C; Xu H; He H; Zhang Y
Int J Pharm; 2012 May; 427(2):234-41. PubMed ID: 22349049
[TBL] [Abstract][Full Text] [Related]
13. Growth factor release by vesicular phospholipid gels: in-vitro results and application for rotator cuff repair in a rat model.
Buchmann S; Sandmann GH; Walz L; Reichel T; Beitzel K; Wexel G; Tian W; Battmann A; Vogt S; Winter G; Imhoff AB
BMC Musculoskelet Disord; 2015 Apr; 16():82. PubMed ID: 25888096
[TBL] [Abstract][Full Text] [Related]
14. Cationic/Anionic Polyelectrolyte (PLL/PGA) Coated Vesicular Phospholipid Gels (VPGs) Loaded with Cytarabine for Sustained Release and Anti-glioma Effects.
Qi N; Zhang Y; Tang X; Li A
Drug Des Devel Ther; 2020; 14():1825-1836. PubMed ID: 32494124
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of poly-butylcyanoacrylate nanoparticles for oral delivery of thymopentin.
He W; Jiang X; Zhang ZR
J Pharm Sci; 2008 Jun; 97(6):2250-9. PubMed ID: 17853430
[TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin.
Yin Y; Chen D; Qiao M; Lu Z; Hu H
J Control Release; 2006 Dec; 116(3):337-45. PubMed ID: 17097180
[TBL] [Abstract][Full Text] [Related]
17. Development and in vitro evaluation of a liposome based implant formulation for the decapeptide cetrorelix.
Grohganz H; Tho I; Brandl M
Eur J Pharm Biopharm; 2005 Apr; 59(3):439-48. PubMed ID: 15760724
[TBL] [Abstract][Full Text] [Related]
18. [Research on thymopentin-loaded N-trimethyl chitosan nanoparticles administered through mouth].
Tang SW; Yuan XJ; Zhang ZR; Song QG; He Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):885-8. PubMed ID: 17953385
[TBL] [Abstract][Full Text] [Related]
19. [Preparation of sustained release multivesicular liposome for thymopentin and preliminary study on its pharmacokinetics in rats].
Jiao YH; Sun KX; Mu HJ; Wang T; Yao DG; Yuan ZZ
Yao Xue Xue Bao; 2008 Jul; 43(7):756-60. PubMed ID: 18819482
[TBL] [Abstract][Full Text] [Related]
20. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid lipid nanoparticles.
Li YZ; Sun X; Gong T; Liu J; Zuo J; Zhang ZR
Pharm Res; 2010 Sep; 27(9):1977-86. PubMed ID: 20625801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
